Corinne Jenkins
Goldman Sachs Group, Inc., Research Division
And maybe I’ll let you introduce yourselves. And then I’d love if you could just start with a conversation on what you view as the core competencies for Prelude. And how has that informed the portfolio construction and your process kind of for business development over the years?
Krishna Vaddi
Founder, CEO & Director
Thank you. Thank you, Corinne. Thanks for the opportunity to participate in Goldman Conference. The straightforward answer to your question is really to start with why? Because we didn’t build the competencies first, the mission came first. So we really exist to bring better treatment options for patients with cancer, right?
And when you hold that standard seriously, it forces us to build a set of capabilities, right? So it told us that you cannot be — could not be modality constrained because different cancers, different pathways, different vulnerabilities.
So the problems call for different solutions. And so we had to build the capabilities to be able to really design new molecular entities across multiple target classes, not because we really wanted to be a broad technology or target platform, but the patient problem demanded it, right? And it
